HCC Risk Prediction in Chronic HBV With Metabolic Dysfunction

Hepatocellular carcinoma (HCC) risk prediction in patients with chronic hepatitis B virus (HBV) infection who also have metabolic dysfunction is a complex but crucial aspect of clinical care. This population faces a compounded risk due to the interplay of chronic HBV infection and metabolic comorbidities, such as obesity, diabetes, hypertension, and dyslipidemia. Below is a detailed breakdown of the key factors, tools, and considerations for HCC risk prediction in this unique group:

---

### **1. Dual Disease Burden**

Patients with chronic HBV and metabolic dysfunction represent a high-risk group due to the combined impact of viral and metabolic factors on liver health. This dual burden increases the likelihood of liver-related complications, including cirrhosis and HCC. Effective risk prediction and management are essential to mitigate these outcomes.

---

### **2. Importance of Metabolic Comorbidities**

Metabolic dysfunction-associated conditions—such as overweight, diabetes, hypertension, and dyslipidemia—are significant contributors to adverse liver outcomes in chronic HBV. These conditions exacerbate liver inflammation, fibrosis progression, and overall disease severity, thereby influencing HCC risk.

---

### **3. Role of MASLD**

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), often coexists with chronic HBV. However, MASLD itself does not independently worsen HCC risk beyond the impact of metabolic dysfunction. The presence of steatosis (fatty liver) is not a decisive factor for HCC risk once metabolic dysfunction is accounted for.

---

### **4. Key Determinants of HCC Risk**

Several factors play a critical role in predicting HCC risk in chronic HBV patients with metabolic dysfunction:

• **Cirrhosis:** The presence of cirrhosis is the strongest clinical indicator of HCC risk. Patients with cirrhosis require closer monitoring, even if other risk factors are minimal.
• **Age:** Increasing age is consistently associated with higher HCC risk in this population. Older patients are more likely to develop liver-related complications.
• **Platelet Count:** Low platelet levels reflect advanced liver disease and are linked to a higher HCC risk.
• **Albumin Levels:** Reduced albumin levels indicate impaired liver function and are associated with worse outcomes.
• **Metabolic Factors:** Conditions like diabetes and obesity further amplify the risk.

---

### **5. Risk Prediction Tools: PAGE-B Score**

The PAGE-B score is a validated and practical tool for predicting HCC risk in patients with chronic HBV, including those with metabolic dysfunction. It incorporates key variables such as age, gender, and platelet count, making it simple and accessible for clinical use.

• **Consistency Across Metabolic Conditions:** The predictive performance of the PAGE-B score remains stable across various metabolic comorbidities, reinforcing its reliability in this complex population.
• **Utility Beyond HCC:** The PAGE-B score also correlates with the risk of broader liver-related events, not just HCC, making it a versatile tool.
• **Low-Risk Group Identification:** Patients with low PAGE-B scores and no cirrhosis are at minimal risk of HCC and may avoid intensive surveillance, improving resource efficiency.
• **Residual Risk in Cirrhosis:** Even patients with low PAGE-B scores who have cirrhosis retain a meaningful risk of HCC and require ongoing monitoring.

Other risk models are available, but the PAGE-B score is favored due to its simplicity and widespread applicability.

---

### **6. Personalized Surveillance Approach**

HCC risk is not uniform across all patients with chronic HBV and metabolic dysfunction. A personalized approach to risk stratification and surveillance is essential:

• **High-Risk Patients:** Individuals with cirrhosis, advanced age, low platelet counts, and low albumin levels require intensive monitoring and regular imaging for early HCC detection.
• **Low-Risk Patients:** Those without cirrhosis and with low PAGE-B scores may benefit from less frequent surveillance, reducing unnecessary procedures and healthcare costs.

---

### **7. Implications of Antiviral Therapy**

Antiviral therapy for chronic HBV does not directly increase HCC risk. Instead, associations between antiviral therapy and outcomes reflect the underlying severity of liver disease. Effective antiviral treatment remains a cornerstone of HBV management and can help reduce long-term liver complications.

---

### **8. Addressing Metabolic Dysfunction**

Managing metabolic dysfunction is an important component of reducing HCC risk in this population. Interventions targeting weight loss, glycemic control, lipid management, and blood pressure regulation may mitigate liver-related risks and improve overall outcomes.

---

### **9. Clinical Practice Relevance**

The integration of metabolic assessment with established HBV risk tools, such as the PAGE-B score, enables a more comprehensive approach to HCC risk prediction. This strategy allows clinicians to:

• Identify high-risk patients who need intensive surveillance.
• Avoid over-monitoring low-risk individuals, optimizing healthcare resources.
• Address metabolic comorbidities to reduce long-term liver complications.

---

### **Conclusion**

HCC risk prediction in chronic HBV patients with metabolic dysfunction requires a nuanced approach that considers both viral and metabolic factors. Tools like the PAGE-B score provide a reliable framework for stratifying risk and guiding surveillance strategies. By integrating metabolic management into HBV care, clinicians can further reduce the burden of liver-related complications and improve patient outcomes.